CD4 and prostate neoplasm: Zolochevska et al. reported that in immunocompetent mice, IL-27 gene therapy leads to the recruitment, in prostate tumors, of CD3+CD8+ cells, to a decrease in Gr1+CD11b+CD124+ and Gr1+CD11b+ cells, putative myeloid derived suppressor cells, and CD4+CD25+Foxp3+ cells, potential Treg population [17].